Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-147 Phase 1 in healthy volunteers
NCT03912441Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCD-147 in HER2-positive breast cancer and HER2-positive gastric cancer (4 arms), sponsored by BIOCAD. Primary endpoints: Maximum Tolerated Dose at 28 days, Percentage of volunteers with treatment-emerged adverse events of any grade at 28 days and 2 more. Started Jan 2019; status: completed.
02
Drugs
BCD-147
03
Conditions
HER2-positive breast cancerHER2-positive gastric cancer
Beyond the preview
Go deeper on NCT03912441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912441.